Related Experiment Videos
Trastuzumab and breast cancer: developments and current status
Eriko Tokunaga1, Eiji Oki, Kojiro Nishida
1Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. eriko@surg2.med.kyushu-u.ac.jp
International Journal of Clinical Oncology
|July 20, 2006
Summary
Trastuzumab therapy has transformed breast cancer treatment. This humanized monoclonal antibody targets HER2-positive cancers, showing significant antitumor activity and improving survival in clinical trials.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Trastuzumab is a monoclonal antibody targeting HER2.
- HER2 overexpression occurs in 20-30% of breast cancers.
- HER2 signaling pathways regulate cell growth and survival.
Purpose of the Study:
- To review the developments and current status of trastuzumab-based breast cancer treatment.
- To highlight trastuzumab's efficacy in various clinical settings.
Main Methods:
- Review of preclinical models and clinical trials (Phase II and III).
- Analysis of trastuzumab as monotherapy and in combination with chemotherapy.
Main Results:
- Trastuzumab demonstrates significant antitumor activity and synergy with chemotherapy.
- Clinical trials show trastuzumab's efficacy in metastatic breast cancer, improving survival.
- Ongoing investigations focus on adjuvant, neoadjuvant, and metastatic settings.
Conclusions:
- Trastuzumab has significantly impacted breast cancer therapy.
- Its efficacy is established in metastatic HER2-positive breast cancer.
- Further research is exploring its use in earlier stages of breast cancer.